UBS analyst Joshua Spector lowered the firm’s price target on Chemours (CC) to $17 from $18 and keeps a Buy rating on the shares. Chemours reported better than feared EBITDA, but the dividend cut was unexpected, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC: